Bolt Biotherapeutics (NASDAQ:BOLT) Announces Earnings Results

Bolt Biotherapeutics (NASDAQ:BOLT) announced its quarterly earnings results on Tuesday. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.08), Yahoo Finance reports. Bolt Biotherapeutics had a negative net margin of 556.59% and a negative return on equity of 51.74%. The company had revenue of $1.28 million during the quarter, compared to analysts’ expectations of $1.19 million.

Bolt Biotherapeutics Trading Up 1.3 %

Shares of NASDAQ BOLT traded up $0.01 during trading on Friday, hitting $0.70. 53,982 shares of the company traded hands, compared to its average volume of 178,509. The firm has a market capitalization of $26.69 million, a P/E ratio of -0.42 and a beta of 0.94. The company has a quick ratio of 5.68, a current ratio of 5.68 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average price of $0.73 and a 200-day moving average price of $0.98. Bolt Biotherapeutics has a 1 year low of $0.65 and a 1 year high of $1.56.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on BOLT. SVB Leerink reaffirmed a “market perform” rating and issued a $1.00 target price (down from $3.00) on shares of Bolt Biotherapeutics in a research report on Wednesday, May 15th. Stifel Nicolaus reiterated a “hold” rating and set a $1.50 price target (down previously from $6.00) on shares of Bolt Biotherapeutics in a research note on Wednesday, May 15th. HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Thursday. Guggenheim reissued a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, May 15th. Finally, Leerink Partnrs cut shares of Bolt Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 14th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $3.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.